Competing risk adjustment reduces overestimation of opportunistic infection rates in AIDS.

[1]  G. Satten,et al.  Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. , 1998, The New England journal of medicine.

[2]  C. Sabin,et al.  Is there a general tendency for CD4 lymphocyte decline to speed up during human immunodeficiency virus infection? Evidence from the Italian Seroconversion Study. , 1997, The Journal of infectious diseases.

[3]  A. Mocroft,et al.  Survival of AIDS patients according to type of AIDS-defining event. The AIDS in Europe Study Group. , 1997, International journal of epidemiology.

[4]  C. Katlama,et al.  Survival of European patients with Kaposi's sarcoma as AIDS‐defining condition during the first decade of AIDS , 1997, AIDS.

[5]  J. Phair,et al.  Using multiple decrement models to estimate risk and morbidity from specific AIDS illnesses. Multicenter AIDS Cohort Study (MACS). , 1996, Statistics in medicine.

[6]  R. Salamon,et al.  Predictive value of Toxoplasma gondii antibody titres on the occurrence of toxoplasmic encephalitis in HIV‐infected patients , 1996, AIDS.

[7]  S. Mallal,et al.  Declining incidence and later occurrence of Kaposi's sarcoma among persons with AIDS in Australia: the Australian AIDS cohort , 1996, AIDS.

[8]  S. Buchbinder,et al.  The association between cigarette smoking and selected HIV‐related medical conditions , 1996, AIDS.

[9]  F. Coolen,et al.  Statistical Models Based on Counting Processes. , 1996 .

[10]  J. Phair,et al.  Survival in HIV-Infected Patients Who Have Received Zidovudine: Comparison of Combination Therapy with Sequential Monotherapy and Continued Zidovudine Monotherapy , 1996, Annals of Internal Medicine.

[11]  J. Phair,et al.  Projecting disease when death is likely. , 1996, American journal of epidemiology.

[12]  A. Monforte,et al.  High frequency of non-Hodgkin's lymphoma in patients with HIV-associated Kaposi's sarcoma , 1996, AIDS.

[13]  C. Rouzioux,et al.  High risk of HIV disease progression after infection through a sexual partner with AIDS , 1996, AIDS.

[14]  M. Moroni,et al.  Better efficacy of twice-monthly than monthly aerosolised pentamidine for secondary prophylaxis of Pneumocystis carinii pneumonia in patients with AIDS. An Italian multicentric randomised controlled trial. The Italian PCP Study Group. , 1995, The Journal of infection.

[15]  J. Phair,et al.  The Effect of the Interaction of Acyclovir with Zidovudine on Progression to AIDS and Survival: Analysis of Data in the Multicenter AIDS Cohort Study , 1994, Annals of Internal Medicine.

[16]  I. Tager,et al.  Factors associated with survival in human immunodeficiency virus-infected patients with very low CD4 counts. , 1994, American journal of epidemiology.

[17]  R. Chaisson,et al.  Incidence and natural history of cytomegalovirus disease in patients with advanced human immunodeficiency virus disease treated with zidovudine. The Zidovudine Epidemiology Study Group. , 1992, The Journal of infectious diseases.

[18]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .

[19]  E. Vittinghoff,et al.  Incidence proportion of and risk factors for AIDS patients diagnosed with HIV dementia, central nervous system toxoplasmosis, and cryptococcal meningitis. , 1995, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association.

[20]  David R. Cox,et al.  Regression models and life tables (with discussion , 1972 .